About Us

RIFT Biotherapeutics is developing first-in-class antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments. Currently, the Company is conducting preclinical testing.

Portage, which owns RIFT, serves as Chief Executive Officer, Chief Scientific Officer, and provides project management and financial support. In addition, Portage holds the Chairman and executive member seats on the Board of Directors.

Pipeline

COMPANY
ASSET
INDICATION
STAGE

Logo Rift

ASSET
A
INDICATION
Solid Tumor
STAGE
IND-Enabling

Programs

RIFT Biotherapeutics is focused on developing antibodies that reprogram the tumor microenvironment.  Preclinical experiments have shown that its novel antibody can cause a decrease in myeloid derived suppressor cells and tumor associated macrophages. In turn, this corrects the cytokines profile, normalizes the vascular system in the tumor and leads to an increase in CD8 T cells. The Company is conducting preclinical studies in solid tumor indications.

Leadership

CEO AND Chairman

Dr. Walters has over 20 years of leadership and expertise in oncology/immunology …

Robert has 24 years of experience in the pharmaceutical industry and is …

Briggs W. Morrison, MD has been the Chief Executive Officer of Syndax …